MPM Oncology Impact Management »

Dyne Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Dyne Therapeutics (DYN) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Dyne Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Dyne Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Dyne Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $18M 1.4M 12.65
2025-06-30 $14M 1.4M 9.52

More positions owned by MPM Oncology Impact Management

Madrigal Pharmaceuticals Common (MDGL)
Cullinan Therapeutics Common (CGEM)
Avidity Biosciences Common (RNA)
Trevi Therapeutics Common (TRVI)
Edgewise Therapeutics Common (EWTX)
PTC Therapeutics Common (PTCT)
Zai Lab Adr (ZLAB)
Syndax Pharmaceuticals Common (SNDX)
Oric Pharmaceuticals Common (ORIC)
Tarsus Pharmaceuticals Common (TARS)
Xenon Pharmaceuticals Common (XENE)
Stoke Therapeutics Common (STOK)
Dyne Therapeutics Common (DYN)
Compass Therapeutics Common (CMPX)
Alkermes Common (ALKS)

View all positions for MPM Oncology Impact Management

Top funds holding Dyne Therapeutics

Henderson Group
Vanguard Group
BlackRock
Atlas Venture Life Science Advisors
Fcpm Iii Services B.v.
FMR
State Street Corporation
Siren
TCG Crossover Management
Adage Capital Partners GP
Citadel Advisors
Jpmorgan Chase & Co
Armistice Capital
Marshall Wace
Rtw Investments

View all funds holding Dyne Therapeutics